Recursion Pharmaceuticals, Inc.

NasdaqGS:RXRX 株式レポート

時価総額：US$2.0b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Recursion Pharmaceuticals マネジメント

マネジメント 基準チェック /24

Recursion Pharmaceuticals'の CEO はChris Gibsonで、 Nov2013年に任命され、 の在任期間は 10.58年です。 の年間総報酬は$ 8.61Mで、 6.5%給与と93.5%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の3.1%を直接所有しており、その価値は$ 69.05M 。経営陣と取締役会の平均在任期間はそれぞれ3.2年と9.8年です。

主要情報

Chris Gibson

最高経営責任者

US$8.6m

報酬総額

CEO給与比率6.5%
CEO在任期間10.7yrs
CEOの所有権2.7%
経営陣の平均在職期間3.3yrs
取締役会の平均在任期間9.9yrs

経営陣の近況

Recent updates

Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery

Jun 24

Recursion Pharmaceuticals: Catalysts Are Coming And Success Is A Must

Jun 14

Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%

May 22
Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 12
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate

Apr 10

Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)

Mar 20

Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely

Jan 31
Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely

Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress

Jan 12

Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues

Dec 09
Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues

What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today

May 09
What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today

We Think Recursion Pharmaceuticals (NASDAQ:RXRX) Can Easily Afford To Drive Business Growth

Mar 01
We Think Recursion Pharmaceuticals (NASDAQ:RXRX) Can Easily Afford To Drive Business Growth

Recursion Pharmaceuticals: Destination Unknown

Sep 20

CEO報酬分析

Recursion Pharmaceuticals の収益と比較して、Chris Gibson の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2024n/an/a

-US$354m

Dec 31 2023US$9mUS$561k

-US$328m

Sep 30 2023n/an/a

-US$293m

Jun 30 2023n/an/a

-US$260m

Mar 31 2023n/an/a

-US$249m

Dec 31 2022US$6mUS$498k

-US$239m

Sep 30 2022n/an/a

-US$247m

Jun 30 2022n/an/a

-US$234m

Mar 31 2022n/an/a

-US$212m

Dec 31 2021US$674kUS$485k

-US$186m

Sep 30 2021n/an/a

-US$147m

Jun 30 2021n/an/a

-US$124m

Mar 31 2021n/an/a

-US$99m

Dec 31 2020US$3mUS$270k

-US$87m

報酬と市場: Chrisの 総報酬 ($USD 8.61M ) は、 US市場 ($USD 5.67M ) の同規模の企業の平均を上回っています。

報酬と収益: Chrisの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Chris Gibson (41 yo)

10.7yrs

在職期間

US$8,613,208

報酬

Dr. Christopher C. Gibson, also known as, Chris, Ph.D. is a Co-Founder of Recursion Pharmaceuticals Inc and serves as its Chief Executive Officer and Director since November 2013. Previously, Dr. Gibson wa...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Christopher Gibson
Co-Founder10.7yrsUS$8.61m2.75%
$ 54.1m
Tina Larson
COO & President6yrsUS$4.87m0.053%
$ 1.0m
Blake Borgeson
Co-Founder & Director11.5yrsUS$292.74k2.67%
$ 52.6m
Michael Secora
Chief Financial Officer4.3yrsUS$4.51m0.35%
$ 6.9m
David Mauro
Chief Medical Officer1.1yrsUS$4.53m0.0024%
$ 46.9k
Kevin Leggat
Vice President of Finance & Accountingno dataデータなしデータなし
Benjamin Mabey
Chief Technology Officer4.5yrsデータなしデータなし
Jared Allenbach
Senior Director of Investor Relations2.2yrsデータなしデータなし
Nathan Hatfield
Chief Legal Officer & General Counselless than a yearデータなしデータなし
Ryan Kelly
Chief Communications Officer2.2yrsデータなしデータなし
Matthew Kinn
Chief Corporate Development Officer and SVP of Business Development & Corporate Initiativesless than a yearデータなしデータなし
Janelle Gordon
Vice President of People Operationsno dataデータなしデータなし

3.3yrs

平均在職期間

41.5yo

平均年齢

経験豊富な経営陣: RXRXの経営陣は 経験豊富 であると考えられます ( 3.2年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Christopher Gibson
Co-Founder10.7yrsUS$8.61m2.75%
$ 54.1m
Blake Borgeson
Co-Founder & Director11.5yrsUS$292.74k2.67%
$ 52.6m
Najat Khan
Chief R&D Officerless than a yearデータなしデータなし
Robert Lollini
Member of Business Advisory Panel9.7yrsデータなしデータなし
H. Fell
Member of Business Advisory Panel10.1yrsデータなしデータなし
Joseph Miletich
Chairman of Therapeutics Advisory Board3yrsデータなしデータなし
Robert Hershberg
Independent Chairman4.3yrsUS$302.74k0.014%
$ 283.9k
Dean Li
Co-Founder & Independent Director10.7yrsUS$300.25k1.18%
$ 23.3m
Anne Carpenter
Member of Scientific and Technical Advisory Board10.3yrsデータなしデータなし
Kirk Thomas
Member of Scientific & Technical Advisory Board10.3yrsデータなしデータなし
Zavain Dar
Independent Director7.8yrsUS$307.74k0.033%
$ 654.5k
Terry-Ann Burrell
Independent Director4.3yrsUS$307.74k0.021%
$ 413.8k

9.9yrs

平均在職期間

61yo

平均年齢

経験豊富なボード: RXRXの 取締役会 は 経験豊富 であると考えられます ( 9.8年の平均在任期間)。